“Our research partnership with Lonza continues to build a robust bank of scientific evidence on the impact of L-carnitine on canine exercise performance and recovery. One of the key findings of this latest study is L-carnitine’s influence on body composition. The ability of L-carnitine to help the body use expendable tissue, namely fat, for energy while preserving lean muscle mass has exciting implications for energy expenditure, weight management and endurance. While the study clearly demonstrated the benefits of L-carnitine for both male and female active dogs, it generated exceptional results in females – an area that has thus far been largely unexplored.”
“This study is the first time we have seen Carniking® premix’s influence on protein turnover evaluated and the difference in oxygen consumption and energy expenditure between male and female subjects studied. The results of the research are particularly significant when we consider the benefits of Carniking® premix supplementation for highly active dogs – where maximizing energy expenditure and maintaining lean muscle mass is essential to animal performance and health.”
Morristown, NJ (USA), April 28th, 2021 – A new scientific study funded by Lonza has shown that daily supplementation with its 250mg Carniking® premix ingredient may increase muscle fat oxidation, inhibit muscle catabolism and increase energy expenditure in highly active dogs.
As a result of high exercise requirements, working or highly active dogs can be at risk of muscle wasting due to entering a negative energy balance. This has implications on the animal’s performance, endurance and recovery, and therefore overall health and wellbeing. The latest research by Lonza demonstrates that daily Carniking® premix supplementation can address this by enabling better utilization of dietary fat for energy production, which in turn may allow active dogs to exercise for longer periods of time while recovering more efficiently.
Published in the peer-reviewed Journal of Animal Physiology and Animal Nutrition, the study was conducted at Four Rivers Kennel in Nevada, Missouri (USA), using Labrador Retrievers – a typical working and service dog. Building on evidence from Lonza and Four Rivers Kennel’s previous research, in this new cross-over placebo-controlled study, dogs were given a series of exercise and running programs, with one group having daily supplementation of 250mg Carniking® premix, providing 125 mg elemental carnitine.
The results showed that Carniking® premix helped to maintain lean muscle mass and reduce muscle damage after exercise by increasing the total, free and esterified L-carnitine in the muscle and serum. The latest research also showed that muscle damage or degradation following running exercise was significantly reduced in dogs supplemented with L-carnitine when compared with placebo.
Furthermore, Carniking® premix was shown to influence the lean muscle mass by determining protein turnover, a key indicator of muscle synthesis. Dogs supplemented with Carniking® premix were also shown to be more efficient at using energy from their food (as measured by VO2 max for aerobic endurance). As a result, they are able to exercise for longer and recover faster.
Lonza holds U.S. Patent 10,016,382 for L-carnitine use in pet food for its beneficial impact on performance and recovery in active dogs. L-carnitine also has an ingredient definition by the Association of American Feed Control Officers (AAFCO) for use in the manufacturing of dog foods, wet and dry treats, and in complete feeds, base mixes or premixes.
More information about Carniking® premix and Lonza’s range of ingredients for animal nutrition can be found at www.lonza.com.
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 8929
victoria.morgan@lonza.com
Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel +41 79 421 1609
dirk.oehlers@lonza.com
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.